A vaccine administered during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to generate protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity offers newborns with instant defence from the moment of birth, exactly when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.
- Nearly 85 per cent protection when vaccinated 4 weeks before birth
- Antibodies from the mother passed through placenta safeguard newborns from birth
- Protection possible with 2-week gap before premature birth
- Vaccination during the third trimester still provides significant protection for infants
Compelling evidence from recent research
The performance of the pregnancy RSV vaccine has been demonstrated through a extensive research programme carried out throughout England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately 90 per cent of all births during that six-month period, providing comprehensive and reliable evidence of the vaccine’s practical effectiveness. The study’s conclusions have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their most vulnerable early months. The scope of this study offers healthcare professionals and parents-to-be with confidence in the vaccine’s established performance across different groups and contexts.
The results present a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV during the study period, with the great majority being infants whose mothers did not receive the vaccination. This stark contrast underscores the vaccine’s critical role in protecting against serious illness in newborns. The drop in hospital admissions above 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Methodology and scope of study
The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospital admissions. The large sample size and comprehensive nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than individual cases or limited subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology measured real-world outcomes rather than laboratory-based settings, providing tangible evidence of how the vaccine functions when delivered across varied healthcare environments and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and its risks
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.
The infection produces deep inflammation in the lungs and airways, making it extremely challenging for affected infants to feed and breathe adequately. Parents often witness their babies visibly struggling, their chests heaving as they work to get enough air into their weakened respiratory system. Whilst most infants get better with palliative treatment, a limited though important proportion perish from RSV-related complications each year, making vaccination as prevention a essential public health priority for protecting the youngest and most vulnerable people in our communities.
- RSV produces inflammation in lungs, causing severe breathing difficulties in infants
- Approximately half of newborns contract the infection in their first few months of life
- Symptoms range from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK babies need serious hospital treatment for RSV each year
- A small number of babies die from RSV complications each year in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have highlighted the importance of pregnant women getting their jab at the ideal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing matters greatly for guaranteeing newborns receive the strongest possible immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery delivers approximately 85% protection, experts encourage women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to enhance the antibodies passed to their babies via the placenta.
The messaging from health authorities stays clear: pregnant women ought to prioritise getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those delivering slightly early. This flexible approach acknowledges the practical demands of pregnancy whilst ensuring strong protection for at-risk infants during their most critical early months when RSV poses the greatest risk of severe infection.
Regional differences in immunisation
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have varied across various areas and NHS trusts. Certain regions have achieved higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to boost understanding and availability of the jab. These regional differences reflect differences across healthcare infrastructure, communication strategies, and local engagement efforts, though the national data demonstrates consistently strong protection regardless of geographical location.
- NHS trusts launching diverse outreach initiatives to engage with expectant mothers
- Geographic variations in immunisation take-up throughout England demand focused enhancement
- Regional health providers tailoring initiatives to meet community needs and circumstances
Practical implications and parent viewpoints
The vaccine’s remarkable effectiveness delivers tangible benefits for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the rollout of this preventative solution, the 80% decrease in admissions represents thousands of infants spared from severe infection. Parents no longer face the upsetting situation of watching their newborns struggle for breath or difficulty feeding, symptoms that define severe RSV infections. The vaccine has markedly changed the terrain of neonatal breathing health, providing expectant mothers a proactive tool to protect their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose acute RSV infection resulted in profound brain damage, the vaccine’s availability carries significant emotional significance. His mother’s support of the jab highlights the profound consequences that vaccine-preventable disease can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story strikes a chord with parents now given protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to expectant mothers during their late pregnancy, changing what was once an predictable seasonal threat into a controllable health concern.